While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Patient outcomes following the diagnosis of multiple myeloma have improved markedly over recent years, but racial and ethnic disparities exist.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.
Notably, peripheral neuropathy — a common AE with proteasome inhibitors — had a low occurrence rate.
Still unresolved is whether to screen the general population for MGUS, a largely asymptomatic condition usually noted during routine blood testing.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Pomalidomide, an immunomodulatory agent with anti-myeloma activity, is metabolized primarily by the liver, suggesting that patients with renal impairment can safely receive the drug.
Patients with quad- or penta-refractory myeloma have limited treatment options. Selinexor, an orally administered selective inhibitor of exportin 1 (XPO1), previously showed anti-myeloma activity in a phase 1 trial.
Studying how MGUS and myeloma clones change over time might yield new insights into myeloma's molecular heterogeneity.
MGUS is a relatively common condition occurring in over 3% of persons age 50 or older which predisposes patients to increased risk of malignant plasma cell transformation.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Denosumab is also indicated for skeletal-related event prevention among patients with bone metastases from solid tumors.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
Disruptions of the p53 tumor suppressor pathway play a key role in tumorigenesis and tumor progression in solid and hematologic malignancies.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
Ajai Chari, MD, discusses his findings at the ASH 2017 meeting in Atlanta.
Jesus San Miguel, MD, PhD, discusses his presentation at the ASH 2017 meeting in Atlanta.
The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.
A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.
Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.
Ninety-five percent of patients received elotuzumab at the increased rate of 5 mL/min without any incidence of IR.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
Cancer Therapy Advisor interviews Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), about the LLS's research directions and how the treatment of hematologic malignancies is changing.
Study results suggest that many patients with multiple myeloma should proceed directly to autologous stem cell transplantation after first-line therapy.
A previous study demonstrated that patients with relapsed MM have a superior PFS and greater depth of response when treated with D-VMP.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy